Please assess the completion status of the following clinical trial:

Trial Title: A Trial of Percutaneous vs. Endoscopic Drainage of Suspected Klatskin Tumors

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Age ≥40 (to reduce the likelihood of enrolling patients with obstruction due to primary sclerosing cholangitis)~2. Cholestatic liver function tests, including serum alkaline phosphatase level ≥ 300 IU/L and bilirubin level ≥ 3.7 mg/dL~3. Radiographic evidence of a biliary hilar stricture OR intrahepatic but no extrahepatic biliary ductal dilation~Exclusion Criteria:~1. Known radiographic evidence of a Bismuth-Corlette type 1 biliary stricture~2. Known diagnosis of primary sclerosing cholangitis without suspicion of dominant hilar stricture~3. Recent gallbladder/biliary surgery within 12 months~4. Known Mirizzi syndrome~5. Known IgG4-mediated cholangiopathy~6. Significant liver metastatic disease interfering with safe/effective PTBD~7. Significant ascites interfering with safe/effective PTBD~8. Known regional malignant-appearing adenopathy or extra-biliary mass, indicating the need for concurrent EUS-FNA~9. Prior ERCP or PTBD for hilar obstruction~10. Surgically altered luminal anatomy other than prior Billroth reconstruction or Whipple resection~11. Standard general contraindications to ERCP or PTBD (e.g. hemodynamic instability, uncorrected coagulopathy, etc.)~12. Inability or unwillingness to follow study protocol

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Percutaneous Transhepatic Drainage (Type: ACTIVE_COMPARATOR): Subjects randomized to this arm will undergo PTBD as the first drainage intervention.
- Endoscopic Retrograde Cholangiography (Type: ACTIVE_COMPARATOR): Subjects randomized to this arm will undergo ERC as the first drainage intervention.

Based on this trial design, predict the completion outcome and termination type (if applicable).